Special Issue

Linking Genomic Changes with Cancer in the NGS Era, 2nd Edition

Message from the Guest Editors

The arrival of next-generation sequencing (NGS) technology has greatly enhanced our ability to read genetic code, starting a new era in identifying disease-causing genetic changes. While detecting individual genetic changes has improved, translating these findings remains complex, particularly in cancer research. Establishing new driver genes or variants is a significant NGS-based screening bottleneck. Only a small fraction of the 10–20% of cancers associated with familial aggregation have known genetic causes, and the genomic profile of the 80–90% of sporadic cancers is highly heterogeneous, complicating the identification of driving versus secondary or progression-associated changes.

In this Special Issue, we invite researchers to submit studies on the identification of new genes or variants linked to cancer development or progression. We welcome evidence from case–control studies, segregation analyses, gene editing (e.g., CRISPR/Cas9), protein structure analyses, functional studies, or other approaches relevant for validating gene–disease associations.

Guest Editors

Prof. Dr. Javier Azúa-Romeo

1. Department of Human Anatomy and Histology, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain
2. Department of Pathology, Analiza, 28001 Madrid, Spain

Dr. Paula Paulo

Cancer Genetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal

Deadline for manuscript submissions

closed (31 August 2025)

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/si/212830

Current Issues in Molecular Biology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

mdpi.com/journal/cimb

Current Issues in Molecular Biology

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed

mdpi.com/journal/cimb

MDPI

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia
Department of Pathology and Molecular Medicine, University of Otago, Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.